RFL
Rafael Holdings, Inc.NYSEReal EstateAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.79
P/S
38.55
EV/EBITDA
-0.22
DCF Value
$1.03
FCF Yield
-62.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
79.8%
Operating Margin
-3050.0%
Net Margin
-2846.6%
ROE
-39.0%
ROA
-42.2%
ROIC
-37.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $211.0K | $-6.4M | $-0.13 |
| Q1 2026 | $240.0K | $-9.8M | $-0.19 |
| Q4 2025 | $350.0K | $-12.1M | $-0.28 |
| FY 2025 | $917.0K | $-30.5M | $-1.04 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Real Estate
Industry
—
Country
US
Exchange
NYSE
Beta
0.51
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.